Logo image of APLS

APELLIS PHARMACEUTICALS INC (APLS) Stock Fundamental Analysis

NASDAQ:APLS - Nasdaq - US03753U1060 - Common Stock - Currency: USD

24.2  -0.06 (-0.25%)

After market: 24.01 -0.19 (-0.79%)

Fundamental Rating

3

APLS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. Both the profitability and financial health of APLS have multiple concerns. APLS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year APLS has reported negative net income.
In the past year APLS has reported a negative cash flow from operations.
In the past 5 years APLS always reported negative net income.
APLS had a negative operating cash flow in each of the past 5 years.
APLS Yearly Net Income VS EBIT VS OCF VS FCFAPLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

APLS's Return On Assets of -27.71% is fine compared to the rest of the industry. APLS outperforms 70.05% of its industry peers.
With a Return On Equity value of -136.21%, APLS is not doing good in the industry: 60.62% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -27.71%
ROE -136.21%
ROIC N/A
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
APLS Yearly ROA, ROE, ROICAPLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

Looking at the Gross Margin, with a value of 83.00%, APLS belongs to the top of the industry, outperforming 87.11% of the companies in the same industry.
APLS's Gross Margin has declined in the last couple of years.
APLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
APLS Yearly Profit, Operating, Gross MarginsAPLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

APLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APLS has been increased compared to 1 year ago.
The number of shares outstanding for APLS has been increased compared to 5 years ago.
The debt/assets ratio for APLS has been reduced compared to a year ago.
APLS Yearly Shares OutstandingAPLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
APLS Yearly Total Debt VS Total AssetsAPLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -1.56, we must say that APLS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of APLS (-1.56) is comparable to the rest of the industry.
A Debt/Equity ratio of 2.76 is on the high side and indicates that APLS has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 2.76, APLS is doing worse than 82.03% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.76
Debt/FCF N/A
Altman-Z -1.56
ROIC/WACCN/A
WACC10.84%
APLS Yearly LT Debt VS Equity VS FCFAPLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

2.3 Liquidity

A Current Ratio of 4.08 indicates that APLS has no problem at all paying its short term obligations.
APLS's Current ratio of 4.08 is in line compared to the rest of the industry. APLS outperforms 46.46% of its industry peers.
A Quick Ratio of 3.62 indicates that APLS has no problem at all paying its short term obligations.
With a Quick ratio value of 3.62, APLS perfoms like the industry average, outperforming 44.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.08
Quick Ratio 3.62
APLS Yearly Current Assets VS Current LiabilitesAPLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

APLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.00%, which is quite impressive.
APLS shows a strong growth in Revenue. In the last year, the Revenue has grown by 97.02%.
APLS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 127.23% yearly.
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.86%
Revenue 1Y (TTM)97.02%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%-10.61%

3.2 Future

The Earnings Per Share is expected to grow by 31.59% on average over the next years. This is a very strong growth
Based on estimates for the next years, APLS will show a quite strong growth in Revenue. The Revenue will grow by 16.21% on average per year.
EPS Next Y-21.41%
EPS Next 2Y23.32%
EPS Next 3Y36%
EPS Next 5Y31.59%
Revenue Next Year10.71%
Revenue Next 2Y10.61%
Revenue Next 3Y14.39%
Revenue Next 5Y16.21%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
APLS Yearly Revenue VS EstimatesAPLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
APLS Yearly EPS VS EstimatesAPLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

APLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year APLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APLS Price Earnings VS Forward Price EarningsAPLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APLS Per share dataAPLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

APLS's earnings are expected to grow with 36.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.32%
EPS Next 3Y36%

More info and screens

0

5. Dividend

5.1 Amount

APLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APELLIS PHARMACEUTICALS INC

NASDAQ:APLS (8/5/2025, 8:00:00 PM)

After market: 24.01 -0.19 (-0.79%)

24.2

-0.06 (-0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners102.48%
Inst Owner Change0.2%
Ins Owners3.77%
Ins Owner Change0.03%
Market Cap3.04B
Analysts77.86
Price Target36.24 (49.75%)
Short Float %15.47%
Short Ratio7.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-37.55%
Min EPS beat(2)-101.36%
Max EPS beat(2)26.26%
EPS beat(4)2
Avg EPS beat(4)-27.55%
Min EPS beat(4)-101.36%
Max EPS beat(4)26.26%
EPS beat(8)4
Avg EPS beat(8)-14.05%
EPS beat(12)5
Avg EPS beat(12)-11.13%
EPS beat(16)5
Avg EPS beat(16)-14.48%
Revenue beat(2)1
Avg Revenue beat(2)-5.68%
Min Revenue beat(2)-16.4%
Max Revenue beat(2)5.05%
Revenue beat(4)2
Avg Revenue beat(4)-3.15%
Min Revenue beat(4)-16.4%
Max Revenue beat(4)5.05%
Revenue beat(8)5
Avg Revenue beat(8)4.07%
Revenue beat(12)7
Avg Revenue beat(12)7.23%
Revenue beat(16)10
Avg Revenue beat(16)41.69%
PT rev (1m)0.45%
PT rev (3m)-15.52%
EPS NQ rev (1m)-0.79%
EPS NQ rev (3m)-82.46%
EPS NY rev (1m)11.63%
EPS NY rev (3m)-70.64%
Revenue NQ rev (1m)0.39%
Revenue NQ rev (3m)-11.01%
Revenue NY rev (1m)9.73%
Revenue NY rev (3m)-1.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.92
P/FCF N/A
P/OCF N/A
P/B 18.52
P/tB 18.52
EV/EBITDA N/A
EPS(TTM)-1.82
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS6.17
BVpS1.31
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.71%
ROE -136.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83%
FCFM N/A
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
F-Score4
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 2.76
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.56%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.08
Quick Ratio 3.62
Altman-Z -1.56
F-Score4
WACC10.84%
ROIC/WACCN/A
Cap/Depr(3y)54.61%
Cap/Depr(5y)218.08%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.86%
EPS Next Y-21.41%
EPS Next 2Y23.32%
EPS Next 3Y36%
EPS Next 5Y31.59%
Revenue 1Y (TTM)97.02%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%-10.61%
Revenue Next Year10.71%
Revenue Next 2Y10.61%
Revenue Next 3Y14.39%
Revenue Next 5Y16.21%
EBIT growth 1Y53.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.6%
EBIT Next 3Y47.79%
EBIT Next 5Y41.5%
FCF growth 1Y98.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y98.57%
OCF growth 3YN/A
OCF growth 5YN/A